European Generics Industry Calls For “Urgent Patent Reform” 11/03/2010 by Intellectual Property Watch Leave a Comment IP-Watch is a non-profit independent news service, and subscribing to our service helps support our goals of bringing more transparency to global IP and innovation policies. To access all of our content, please subscribe now. You also have the opportunity to offer additional support to your subscription, or to donate. “Competition and real innovation” will be increasingly difficult if the patent system in Europe is not reformed, the European Generic Medicines Association (EGA) said today at its “Legal Affairs Forum,” which took place on 11 March. The European Patent Office must “look to improve the quality of patent examinations and applications and accelerate examination and opposition proceedings,” the EGA said in a press release. The EGA in particular supports a so-called “Bolar provision” that would keep market access issues such as marketing authorisation separate from IP issues. The statement comes in the context of the European Union’s pharmaceutical sector inquiry, which found anticompetitive practices rampant in the brand-name pharmaceutical industry, including the active use of intellectual property to delay generic medicines entry into market (IPW, Public Health, 8 July 2009). Follow-up to the inquiry’s findings is ongoing, including antitrust actions such as monitoring patent settlements between pharmaceutical companies, as well as formal proceedings against the pharmaceutical company Lundbeck. "European Generics Industry Calls For “Urgent Patent Reform”" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.